STAT3 in the Pathogenesis and Treatment of Pancreatic Cancer

STAT3在胰腺癌发病机制和治疗中的作用

基本信息

  • 批准号:
    7132182
  • 负责人:
  • 金额:
    $ 12.97万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-06-27 至 2008-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Although pancreatic cancer has the highest case fatality rate of any common human malignancy, relatively little progress has been made in its treatment. To develop more effective and less toxic therapies it is necessary to understand the key molecular abnormalities of cancer cells, and to target these specifically. Recent evidence has indicated that inappropriate activation of the transcription factor STAT3 may be critical to the malignant behavior of pancreatic carcinoma cells. We have identified a cohort of genes that are immediate targets of STAT3, and which are activated as a group in primary human pancreatic cancers. In addition, given the central importance of STAT3 in pancreatic cancer pathogenesis, we have developed a high throughput cell based screen for small molecules that can inhibit the function of STAT3. In the present application we propose to elucidate the role that these STAT3 target genes play in pancreatic cancer biology, and evaluate the molecules we have identified as targeted therapies for this disease. Specifically, we will address three aims: To determine the role of STAT3 target genes in the biology of pancreatic cancer; to elucidate the effect of targeted STAT3 inhibitors on gene expression and phenotype of human pancreatic cancer cells; and, to determine the activity of STAT3 inhibitors in a murine model of pancreatic cancer. Through this work, we aim to enhance our understanding of the molecular underpinnings of pancreatic cancer, and to develop targeted molecular therapy for this disease. Relevance: To enhance the treatment of pancreatic cancer, this proposal will focus on understanding how the abnormal function of a key transcription factor, STAT3, directly contributes to the pathogenesis of this disease. Given the importance of this protein in the biology of pancreatic cancer, we have identified drugs that can specifically inhibit the function of STAT3. We will test these drugs to determine whether they can be prototypes for a novel targeted form of therapy for this disease.
描述(由申请人提供):尽管胰腺癌在任何常见的人类恶性肿瘤中具有最高的病死率,但其治疗进展相对较小。为了开发更有效和毒性更小的治疗方法,有必要了解癌细胞的关键分子异常,并针对这些特异性。最近的证据表明,转录因子STAT 3的不适当激活可能是胰腺癌细胞恶性行为的关键。我们已经确定了一组基因,它们是STAT 3的直接靶点,并且在原发性人类胰腺癌中作为一组被激活。此外,鉴于STAT 3在胰腺癌发病机制中的核心重要性,我们已经开发了一种基于细胞的高通量筛选可以抑制STAT 3功能的小分子的方法。在本申请中,我们提出阐明这些STAT 3靶基因在胰腺癌生物学中发挥的作用,并评估我们已经鉴定为该疾病的靶向疗法的分子。具体而言,我们将解决三个目标:确定STAT 3靶基因在胰腺癌生物学中的作用;阐明靶向STAT 3抑制剂对人胰腺癌细胞基因表达和表型的影响;以及确定STAT 3抑制剂在胰腺癌小鼠模型中的活性。通过这项工作,我们的目标是提高我们对胰腺癌的分子基础的理解,并开发针对这种疾病的靶向分子治疗。相关性:为了加强胰腺癌的治疗,该提案将重点关注关键转录因子STAT 3的异常功能如何直接导致这种疾病的发病机制。鉴于这种蛋白质在胰腺癌生物学中的重要性,我们已经确定了可以特异性抑制STAT 3功能的药物。我们将测试这些药物,以确定它们是否可以成为这种疾病的新型靶向治疗的原型。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID A. FRANK其他文献

DAVID A. FRANK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID A. FRANK', 18)}}的其他基金

Dual STAT3/NF-kB Inhibitors for Targeted Cancer Therapy
用于癌症靶向治疗的 STAT3/NF-kB 双抑制剂
  • 批准号:
    9037605
  • 财政年份:
    2012
  • 资助金额:
    $ 12.97万
  • 项目类别:
Dual STAT3/NF-kB Inhibitors for Targeted Cancer Therapy
用于癌症靶向治疗的 STAT3/NF-kB 双抑制剂
  • 批准号:
    8641668
  • 财政年份:
    2012
  • 资助金额:
    $ 12.97万
  • 项目类别:
Dual STAT3/NF-kB Inhibitors for Targeted Cancer Therapy
用于癌症靶向治疗的 STAT3/NF-kB 双抑制剂
  • 批准号:
    8295417
  • 财政年份:
    2012
  • 资助金额:
    $ 12.97万
  • 项目类别:
Dual STAT3/NF-kB Inhibitors for Targeted Cancer Therapy
用于癌症靶向治疗的 STAT3/NF-kB 双抑制剂
  • 批准号:
    8463484
  • 财政年份:
    2012
  • 资助金额:
    $ 12.97万
  • 项目类别:
STAT3 in the Pathogenesis and Treatment of Pancreatic Cancer
STAT3在胰腺癌发病机制和治疗中的作用
  • 批准号:
    7268155
  • 财政年份:
    2006
  • 资助金额:
    $ 12.97万
  • 项目类别:
High Throughput Screening for Modulators of STAT5 (RMI)
STAT5 调制器的高通量筛选 (RMI)
  • 批准号:
    6879437
  • 财政年份:
    2004
  • 资助金额:
    $ 12.97万
  • 项目类别:
STAT SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA
慢性淋巴细胞白血病中的 STAT 信号转导
  • 批准号:
    2726415
  • 财政年份:
    1999
  • 资助金额:
    $ 12.97万
  • 项目类别:
STAT SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA
慢性淋巴细胞白血病中的 STAT 信号转导
  • 批准号:
    6342108
  • 财政年份:
    1999
  • 资助金额:
    $ 12.97万
  • 项目类别:
STAT SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA
慢性淋巴细胞白血病中的 STAT 信号转导
  • 批准号:
    6137684
  • 财政年份:
    1999
  • 资助金额:
    $ 12.97万
  • 项目类别:
STAT SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA
慢性淋巴细胞白血病中的 STAT 信号转导
  • 批准号:
    6626615
  • 财政年份:
    1999
  • 资助金额:
    $ 12.97万
  • 项目类别:

相似海外基金

Understanding MMP3-rich exosomes on neoplastic cell communication in tumor microenvironment
了解富含 MMP3 的外泌体对肿瘤微环境中肿瘤细胞通讯的影响
  • 批准号:
    22KF0268
  • 财政年份:
    2023
  • 资助金额:
    $ 12.97万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Project 3: Neoplastic Cell Evolution
项目3:肿瘤细胞进化
  • 批准号:
    10392869
  • 财政年份:
    2018
  • 资助金额:
    $ 12.97万
  • 项目类别:
Analysis of neoplastic cell-specific fatal effects with reactive oxygen species abnormality derived from compound from plant species, piperlongumine
植物物种胡椒长明化合物活性氧异常对肿瘤细胞特异性致命影响的分析
  • 批准号:
    15K00537
  • 财政年份:
    2015
  • 资助金额:
    $ 12.97万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Non-neoplastic cell types dictate gliomagenesis and
非肿瘤细胞类型决定神经胶质瘤的发生和
  • 批准号:
    8353539
  • 财政年份:
    2012
  • 资助金额:
    $ 12.97万
  • 项目类别:
Non-neoplastic cell types dictate gliomagenesis and
非肿瘤细胞类型决定神经胶质瘤的发生和
  • 批准号:
    8911787
  • 财政年份:
    2012
  • 资助金额:
    $ 12.97万
  • 项目类别:
Non-neoplastic cell types dictate gliomagenesis and
非肿瘤细胞类型决定神经胶质瘤的发生和
  • 批准号:
    9145472
  • 财政年份:
    2012
  • 资助金额:
    $ 12.97万
  • 项目类别:
Non-neoplastic cell types dictate gliomagenesis and
非肿瘤细胞类型决定神经胶质瘤的发生和
  • 批准号:
    8539471
  • 财政年份:
    2012
  • 资助金额:
    $ 12.97万
  • 项目类别:
Non-neoplastic cell types dictate gliomagenesis and
非肿瘤细胞类型决定神经胶质瘤的发生和
  • 批准号:
    8730564
  • 财政年份:
    2012
  • 资助金额:
    $ 12.97万
  • 项目类别:
Analysis for a new mechanism of neoplastic cell transformation through the centrosome control with MT1-MMP
MT1-MMP 中心体控制肿瘤细胞转化新机制分析
  • 批准号:
    23650592
  • 财政年份:
    2011
  • 资助金额:
    $ 12.97万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Elucidation for molecular mechanisms of neoplastic cell transformation
阐明肿瘤细胞转化的分子机制
  • 批准号:
    23300347
  • 财政年份:
    2011
  • 资助金额:
    $ 12.97万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了